3 completed, 2 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 1 | 1 | Completed 1 |
Follow Neumedicines Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy NM-IL-12 - Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Unknown | Neumedicines Inc. | 12 | 2016-11-01 | 2016-08-03 |
| NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds NM-IL-12, Placebo - Colostomy Stoma | Phase 2 | Completed | Neumedicines Inc. | 18 | 2016-03-01 | 2018-11-16 |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) NM-IL-12 and TSEBT - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Phase 2 | Unknown | Neumedicines Inc. | 10 | 2015-12-01 | 2018-11-16 |
| Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome HemaMax, Placebo - Hematopoietic Syndrome Due to Acute Radiation Syndrome | Phase 2 | Completed | Neumedicines Inc. | 200 | 2015-01-01 | 2018-11-16 |
| Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure HemaMax, Placebo - Hematopoietic Syndrome Due to Acute Radiation Syndrome | Phase 1 | Completed | Neumedicines Inc. | 60 | 2012-08-01 | 2018-11-16 |
Lymphoma (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Recurrence (1) · Sezary Syndrome (1)
Interleukin-12 Subunit p35 (5)
United States (4)
Nicholas Siebers, MD (2) · Grant V Bochicchio, MD, MPH (GB) (1) · Yossef Kalish, MD (1) · Youn H Kim, MD (1)
R44CA192576 (1)